Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
CON
Concentra Group Holdings Parent, Inc.
The business provides diagnostic testing via its clinics, aligning with laboratory testing and diagnostic service capabilities.
|
$2.67B |
$20.86
-1.39%
|
|
BKD
Brookdale Senior Living Inc.
Brookdale provides healthcare services and facilities through its senior living communities, including care delivery and facility management.
|
$2.64B |
$11.13
-1.07%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.63B |
$49.59
-0.36%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.59B |
$46.27
+0.40%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.59B |
$31.73
+1.02%
|
|
LFST
LifeStance Health Group, Inc.
Direct provider of behavioral health outpatient services (therapy, psychiatric evaluations, care coordination).
|
$2.55B |
$6.57
-0.90%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$2.53B |
$25.06
+1.50%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma is a biotech company focused on oncology, developing apoptosis-targeted cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.53B |
$31.01
-4.20%
|
|
ITGR
Integer Holdings Corporation
Integer is a contract development and manufacturing organization (CDMO) for medical devices, directly providing design, development and manufacturing services to OEMs.
|
$2.52B |
$72.09
+0.92%
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.52B |
$28.73
-2.10%
|
|
BBU
Brookfield Business Partners L.P.
Healthscope operates hospital services, a healthcare services/ facilities business.
|
$2.49B |
$33.61
+0.75%
|
|
BBUC
Brookfield Business Corporation
Operates private hospitals and related hospital services.
|
$2.49B |
$34.25
+1.00%
|
|
ATS
ATS Corporation
ATS-related offerings intersect with Medical Devices & Biometrics via automated production of regulated devices.
|
$2.48B |
$25.60
+2.15%
|
|
SPNT
SiriusPoint Ltd.
Accident & Health lines indicate health-related insurance offerings, aligned with Health Insurance.
|
$2.44B |
$20.93
+0.05%
|
|
TXG
10x Genomics, Inc.
TXG directly manufactures and sells diagnostic instrument platforms for single-cell and spatial biology workflows.
|
$2.33B |
$18.76
-1.63%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.31B |
$6.24
-1.27%
|
|
EYE
National Vision Holdings, Inc.
Provides eye care services including eye exams across its store network.
|
$2.30B |
$29.02
+2.17%
|
|
PGNY
Progyny, Inc.
Progyny Rx is an integrated pharmacy benefits solution, aligning with PBM-like capabilities for medications within its program.
|
$2.30B |
$26.69
-0.30%
|
|
XRAY
DENTSPLY SIRONA Inc.
XRAY directly manufactures dental equipment used in clinical practice (imaging, CAD/CAM, etc.), fitting this tag.
|
$2.25B |
$11.29
+1.80%
|
|
BBAI
BigBear.ai Holdings, Inc.
VeriScan biometric traveler processing indicates biometrics/biometric sensing offerings.
|
$2.23B |
$6.01
-2.91%
|
|
ADUS
Addus HomeCare Corporation
Core service line providing Home Health & Hospice care in-home.
|
$2.23B |
$121.00
+0.42%
|
|
GEO
The GEO Group, Inc.
Provides continuum of care rehabilitation and post-release services as part of corrections/rehabilitation programs.
|
$2.21B |
$15.56
-0.32%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$2.20B |
$20.05
+0.78%
|
|
AORT
Artivion, Inc.
Artivion's core business is manufacturing medical devices and implantable tissues across cardiology and vascular platforms.
|
$2.20B |
$46.55
-0.60%
|
|
SGRY
Surgery Partners, Inc.
Operates outpatient surgery centers and ASCs, the core service offering and revenue driver.
|
$2.19B |
$17.09
+1.15%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS (voclosporin) is an immunology/autoimmune therapy, aligning Aurinia's core business with immunology therapeutics.
|
$2.15B |
$16.37
+0.55%
|
|
MD
Pediatrix Medical Group, Inc.
Provides hospital-based neonatal and maternal-fetal care services (NICU care and maternal-fetal medicine) delivered in hospital settings.
|
$2.13B |
$24.48
-0.69%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.13B |
$33.34
+13.30%
|
|
NHC
National HealthCare Corporation
NHC operates integrated healthcare services and facilities, including skilled nursing, home health, hospice, and behavioral health services.
|
$2.13B |
$137.87
-0.06%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.11B |
$12.13
+0.04%
|
|
OSW
OneSpaWorld Holdings Limited
Medi-Spa offerings utilize medical devices and biometrics (e.g., CoolSculpting Elite, Elemis Biotec, LightStim).
|
$2.09B |
$20.39
-1.83%
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$2.08B |
$34.74
+0.01%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.08B |
$21.39
-6.69%
|
|
ZYME
Zymeworks Inc.
Lead ADC programs leverage proprietary antibody-drug conjugate platforms with a defined payload.
|
$2.05B |
$27.34
+4.43%
|
Showing page 10 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
